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A survey of a series of genetic centers in Europe [1]
showed that today a substantial number of samples from
patients are being sent abroad for DNA analysis to
laboratories in Europe, the US or elsewhere in the world.
66% of the 233 laboratories, which replied to the ques-
tionnaire, received samples from other countries and 47%
sent samples to other countries. In absolute numbers this
would mean that about ¼ of all samples cross borders
today. This traffic will only further increase when the
European cross-border directive 2011/24 [2] will be acti-
vated. This directive states that “Member States shall
bring into force the laws, regulations and administrative
provisions necessary to comply with this Directive by
25 October 2013”. The focus of these regulations and
provisions should be on the quality of the services wher-
ever the patients or their samples are being examined [3].
The quality management of the facilities i.e. evidence
that they follow international guidelines, e.g. those pub-
lished in 2007 by the OECD [4] or are accredited under
the ISO 15189; that appropriate pre- and post- testing
counseling is guaranteed, particularly when whole gen-
ome or exome sequencing is considered; and that patient
representatives are involved in the implementation of
these processes, should become compulsory. The Direct
to Consumer (DTC) testing facilities, available through
internet, have forced geneticists to reconsider the way
genetic services are provided. A positive aspect of this
development is that issues, such as information for pro-
spective consumers, counseling and support, consent,
data protection, interpretation of results, and others have
received much more attention than in the past. The
EuroGentest Network of Excellence (NoE), supported by
DG Research (2005 – 2010)and its successor as Coordi-
nation Action (2011-2013), together with the European
Society of Human Genetics, have worked very hard on
the improvement of the quality of the genetic services in
Europe. Nevertheless, such efforts by ‘volunteers’, will
not suffice once the new Directive is in place. To guaran-
tee quality services to the consumers we will need har-
monisation of the services, which can only be achieved at
the European level through the existing facilities of the
commission. There is a need for a regulatory framework
for Quality Assurance (ISO accreditation), for test devel-
opment and use, harmonised legal, regulatory and health-
care policies for pharmacogenetics as well as a the
finalization of the revision of the IVD directive, preferably
in harmony with the ‘Global Health Task Force’.
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